Long term, well get more information, but right now it looks like we have enough information that were not really seeing a significant effect on the fetus, only improvement because we have better glycemic control prior to pregnancy.
This drug is going to expire this year, with its competitive generics ready to enter the market
Promising safety profile: Early trials report tolerability comparable to incretin-based agents, though higher doses are associated with GI side effects (nausea, diarrhea, vomiting, constipation) Clinical Advantage over Others (Clinical Trial Evidence) Phase 2 obesity studies: At 48 weeks, retatrutide delivered weight reductions up to 24%, far exceeding results reported for monotherapy GLP-1 agents
October 2024: The FDA declared the shortage of tirzepatide resolved
Quando usado junto a uma alimentao balanceada e exerccios regulares, pode ajudar a manter uma rotina de atividade fsica sustentvel